Related Experiment Video
Updated: May 23, 2026
09:39
A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
Published on: December 27, 2016
Towards diagnostic guidelines for biofilm-associated infections
Luanne Hall-Stoodley1, Paul Stoodley, Sandeep Kathju
1Wellcome Trust Clinical Research Facility, University Hospital Southampton Foundation Trust, Southampton, UK. L.Hall-Stoodley@soton.ac.uk
FEMS Immunology and Medical Microbiology
|April 4, 2012
Summary
Biofilm-associated infections (BAI) are challenging due to antibiotic resistance. Developing better diagnostic markers is crucial for effective treatment and reducing healthcare costs.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Translational Medicine
Background:
- Biofilms in sterile human body sites are difficult to diagnose and treat.
- Recalcitrance to antibiotics and host immune responses complicate management.
- A translational approach is needed for studying clinically relevant biofilms.
Purpose of the Study:
- To provide an overview of biofilm-associated infections (BAI).
- To propose a platform for advancing BAI diagnosis and treatment.
- To highlight the need for improved diagnostic markers.
Main Methods:
- Review of current understanding of clinical biofilms.
- Discussion synthesis from the 5th ASM Biofilm Conference.
- Focus on differences between planktonic and biofilm cells for diagnostics.
Main Results:
- Biofilms pose significant diagnostic and therapeutic challenges.
- A multidisciplinary approach involving clinicians and researchers is essential.
- Exploiting differences between planktonic and biofilm cells may yield better diagnostics.
Conclusions:
- Effective management of BAI requires a translational research approach.
- Development of novel diagnostic markers is critical for improved patient outcomes.
- Mitigating the human and economic costs of BAI is a key objective.
